|
IN184589B
(US07585860-20090908-C00112.png)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
|
WO2001037804A2
(en)
*
|
1999-11-22 |
2001-05-31 |
Universal Preservation Technologies, Inc. |
Preservation and formulation of bioactive materials
|
|
AU4346101A
(en)
*
|
2000-03-07 |
2001-09-17 |
Merck & Co., Inc. |
Adenovirus formulations
|
|
US7456009B2
(en)
*
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
|
US7153472B1
(en)
|
2000-11-22 |
2006-12-26 |
Quadrant Drug Delivery Limited |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
|
US6827250B2
(en)
*
|
2001-06-28 |
2004-12-07 |
Microchips, Inc. |
Methods for hermetically sealing microchip reservoir devices
|
|
US7354597B2
(en)
*
|
2001-12-03 |
2008-04-08 |
Massachusetts Institute Of Technology |
Microscale lyophilization and drying methods for the stabilization of molecules
|
|
EP1534213B1
(en)
*
|
2002-03-13 |
2013-04-24 |
Sköld, Thomas |
Water-based delivery systems
|
|
CA2495327C
(en)
*
|
2002-08-16 |
2008-10-21 |
Microchips, Inc. |
Controlled release device and method using electrothermal ablation
|
|
US7497855B2
(en)
*
|
2002-09-04 |
2009-03-03 |
Microchips, Inc. |
Method and device for the controlled delivery of parathyroid hormone
|
|
PL212483B1
(pl)
*
|
2002-09-27 |
2012-10-31 |
Powderject Res Ltd |
Sposób wytwarzania czasteczek, czasteczki odpowiednie do dostarczania, pojemnik, urzadzenie do dostarczania czasteczek i zastosowanie tych czasteczek
|
|
AU2003284018A1
(en)
|
2002-10-04 |
2004-05-04 |
Microchips, Inc. |
Medical device for neural stimulation and controlled drug delivery
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
AU2003299795A1
(en)
|
2002-12-20 |
2004-07-22 |
Xeris Pharmaceuticals, Inc. |
Intracutaneous injection
|
|
EP1624883A4
(en)
*
|
2003-04-09 |
2008-11-26 |
Univ Utah Res Found |
COMPOSITIONS AND METHODS RELATING TO THE PRODUCTION OF ERYTHROPOIETIN
|
|
US20040247671A1
(en)
*
|
2003-04-25 |
2004-12-09 |
Prescott James H. |
Solid drug formulation and device for storage and controlled delivery thereof
|
|
US7892205B2
(en)
|
2003-06-06 |
2011-02-22 |
Boston Scientific Scimed, Inc. |
Device and method for delivering micronized therapeutic agents in the body
|
|
JP2007512859A
(ja)
*
|
2003-11-03 |
2007-05-24 |
マイクロチップス・インコーポレーテッド |
グルコースを感知するための医療デバイス
|
|
EP1765455A2
(en)
*
|
2004-06-01 |
2007-03-28 |
Microchips, Inc. |
Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
|
|
WO2006015299A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Microchips, Inc. |
Multi-reservoir device for transdermal drug delivery and sensing
|
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
|
EP1791643B1
(en)
*
|
2004-09-01 |
2009-03-11 |
Microchips, Inc. |
Multi-cap reservoir devices for controlled release or exposure of reservoir contents
|
|
MX2007002925A
(es)
*
|
2004-09-10 |
2007-08-14 |
Becton Dickinson Co |
Dispositivo de infusion reconstituyente.
|
|
EP1843783B1
(en)
|
2005-01-25 |
2012-05-30 |
MicroCHIPS, Inc. |
Control of drug release by transient modification of local microenvironments
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
AU2006330526B2
(en)
*
|
2005-12-22 |
2012-09-27 |
Oakwood Laboratories, Llc |
Sublimable sustained release delivery system and method of making same
|
|
MX2008014870A
(es)
|
2006-05-30 |
2009-02-12 |
Intarcia Therapeutics Inc |
Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
|
|
ES2422864T3
(es)
|
2006-08-09 |
2013-09-16 |
Intarcia Therapeutics, Inc |
Sistemas de liberación osmótica y unidades de pistón
|
|
EP2134353B1
(en)
*
|
2007-03-30 |
2016-11-16 |
Helix Biopharma Corp. |
Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
|
|
AU2008244523B2
(en)
|
2007-04-23 |
2012-02-16 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
WO2009002874A1
(en)
|
2007-06-22 |
2008-12-31 |
Board Of Regents, The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
|
US8343140B2
(en)
|
2008-02-13 |
2013-01-01 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
WO2010056657A2
(en)
|
2008-11-16 |
2010-05-20 |
Board Of Regents, The Univesity Of Texas System |
Low viscosity highly concentrated suspensions
|
|
ES2866623T3
(es)
*
|
2008-11-24 |
2021-10-19 |
Massachusetts Inst Technology |
Métodos y composiciones para el suministro localizado de nanopartículas a un tumor
|
|
EP3735944A1
(en)
|
2009-09-28 |
2020-11-11 |
Intarcia Therapeutics, Inc. |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
|
US20110223208A1
(en)
*
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
|
EP2544721B1
(en)
*
|
2010-03-09 |
2017-12-06 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations
|
|
ES2564502T3
(es)
|
2010-03-17 |
2016-03-23 |
Novaliq Gmbh |
Composición farmacéutica para el tratamiento de la presión intraocular aumentada
|
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
|
EP2462921A1
(en)
|
2010-11-11 |
2012-06-13 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the treatment of a posterior eye disease
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
EA028572B1
(ru)
|
2011-03-10 |
2017-12-29 |
Ксерис Фармасьютикалс, Инк. |
Стабильная композиция для парентеральной инъекции и способы ее получения и использования
|
|
ES2962524T3
(es)
|
2011-05-25 |
2024-03-19 |
Dermaliq Therapeutics Inc |
Composición farmacéutica tópica a base de alcanos semifluorados
|
|
EP2714008B1
(en)
|
2011-05-25 |
2016-12-14 |
Novaliq GmbH |
Pharmaceutical composition for administration to nails
|
|
CN103930096B
(zh)
|
2011-10-31 |
2017-05-31 |
Xeris药物公司 |
用于治疗糖尿病的制剂
|
|
DK2806886T3
(en)
|
2012-01-23 |
2017-06-06 |
Novaliq Gmbh |
STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
|
|
US9125805B2
(en)
|
2012-06-27 |
2015-09-08 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of small molecule drugs
|
|
DK2895144T3
(en)
|
2012-09-12 |
2017-03-06 |
Novaliq Gmbh |
SEMIFLUORED ALKAN COMPOSITIONS
|
|
EP3100722B1
(en)
|
2012-09-12 |
2024-03-20 |
Novaliq GmbH |
Semifluorinated alkanes for use in solubilizing meibum
|
|
JP6542128B2
(ja)
|
2013-01-11 |
2019-07-10 |
コルセア ファーマ インコーポレイテッド |
トレプロスチニルのプロドラッグ
|
|
US9505737B2
(en)
|
2013-01-11 |
2016-11-29 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
|
EA037906B1
(ru)
|
2013-03-15 |
2021-06-04 |
Биовератив Терапьютикс Инк. |
Препараты полипептида фактора ix
|
|
CN105555311B
(zh)
|
2013-07-23 |
2021-10-08 |
诺瓦利克有限责任公司 |
稳定的抗体组合物
|
|
US10159646B2
(en)
|
2013-08-12 |
2018-12-25 |
Altum-Avro Pharma Partnership |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
|
US8986732B2
(en)
|
2013-08-12 |
2015-03-24 |
Helix Biopharma Corporation |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
|
KR102435648B1
(ko)
|
2013-09-11 |
2022-08-25 |
이글 바이오로직스 인코퍼레이티드 |
점도저하제를 함유하는 액체 단백질 제형
|
|
CA2925304C
(en)
|
2013-09-27 |
2023-04-18 |
Massachusetts Institute Of Technology |
Carrier-free biologically-active protein nanostructures
|
|
AU2015236340B2
(en)
*
|
2014-03-24 |
2020-02-06 |
Bioverativ Therapeutics Inc. |
Lyophilized factor IX formulations
|
|
WO2016010538A1
(en)
|
2014-07-16 |
2016-01-21 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
|
WO2016022831A1
(en)
|
2014-08-06 |
2016-02-11 |
Xeris Pharmaceuticals, Inc. |
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
SG11201702614SA
(en)
|
2014-10-01 |
2017-04-27 |
Eagle Biolog Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
|
EP4278996A3
(en)
|
2015-06-03 |
2024-01-24 |
i2o Therapeutics, Inc. |
Implant placement systems
|
|
US9649364B2
(en)
|
2015-09-25 |
2017-05-16 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
|
US9643911B2
(en)
|
2015-06-17 |
2017-05-09 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
|
US9394227B1
(en)
|
2015-06-17 |
2016-07-19 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
|
US11034752B2
(en)
|
2015-08-12 |
2021-06-15 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
|
US11590205B2
(en)
|
2015-09-25 |
2023-02-28 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
|
|
DK3355990T3
(da)
|
2015-09-30 |
2019-09-16 |
Novaliq Gmbh |
Semifluorinerede forbindelser og disses sammensætninger
|
|
DE202016008739U1
(de)
|
2015-09-30 |
2019-04-29 |
Novaliq Gmbh |
Semifluorierte Verbindungen
|
|
AU2017268161B2
(en)
|
2016-05-16 |
2020-03-12 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
AU2017283480A1
(en)
|
2016-06-13 |
2019-01-24 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
PT3442480T
(pt)
|
2016-06-23 |
2019-12-23 |
Novaliq Gmbh |
Método de administração tópica
|
|
MX2019003363A
(es)
|
2016-09-22 |
2019-10-02 |
Novaliq Gmbh |
Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
|
|
MX2019003364A
(es)
|
2016-09-23 |
2019-10-02 |
Novaliq Gmbh |
Composiciones oftalmicas que comprenden ciclosporina.
|
|
CA3049034A1
(en)
|
2017-01-03 |
2018-07-12 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
|
|
ES2957559T3
(es)
|
2017-04-21 |
2024-01-22 |
Dermaliq Therapeutics Inc |
Composiciones de yodo
|
|
US11278503B2
(en)
|
2017-05-12 |
2022-03-22 |
Novaliq Gmbh |
Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
|
|
WO2018211517A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
|
AU2018275686B2
(en)
|
2017-06-02 |
2024-02-01 |
Xeris Pharmaceuticals, Inc. |
Precipitation resistant small molecule drug formulations
|
|
WO2019050978A1
(en)
|
2017-09-05 |
2019-03-14 |
Torque Therapeutics, Inc. |
THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF
|
|
US11723861B2
(en)
|
2017-09-27 |
2023-08-15 |
Novaliq Gmbh |
Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
|
|
WO2019068763A1
(en)
|
2017-10-04 |
2019-04-11 |
Novaliq Gmbh |
OPHTHALMIC COMPOSITIONS COMPRISING F6H8
|
|
KR20200128407A
(ko)
|
2018-03-02 |
2020-11-12 |
노바리크 게엠베하 |
네비볼롤을 포함하는 약제학적 조성물
|
|
WO2019217637A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Biomatrica, Inc. |
Stabilization of proteins in biological samples
|
|
SG11202102820VA
(en)
|
2018-10-12 |
2021-04-29 |
Novaliq Gmbh |
Ophthalmic composition for treatment of dry eye disease
|
|
AU2020219125A1
(en)
|
2019-02-05 |
2021-08-12 |
Lindy Biosciences, Inc. |
Isolated cell culture components and methods for isolating the same from liquid cell culture medium
|
|
CN115397480A
(zh)
|
2019-12-06 |
2022-11-25 |
广州倍绣生物技术有限公司 |
可流动纤维蛋白原凝血酶糊剂
|
|
US20230101362A1
(en)
*
|
2021-09-16 |
2023-03-30 |
Team Medical Llc |
Rna stabilization
|
